Parecoxib is an inactive pro-drug that is rapidly converted to valdecoxib, a selective cyclooxygenase (COX)-2 inhibitor registered for the management of post-operative pain in humans. Recent studies have suggested that parecoxib has excellent clinical efficacy and safety in veterinary species. The aim of the current study was to assess the pharmacokinetics of parecoxib and valdecoxib after intravenous (IV) and intramuscular (IM) administration. Seven healthy male Beagle dogs received 2.5 mg/kg parecoxib by either the IV or IM route in a cross-over design, with the alternative route of administration used 1 week later. The plasma concentrations of both analytes were detected according to a previously validated method using high performance liquid chromatography with fluorescence detection (HPLC-FL).
|Autori interni:||GIORGI, MARIO|
|Autori:||Giorgi M; Saccomanni G; Del Carlo S; Manera C; Lavy E.|
|Titolo:||PHARMACOKINETICS OF INTRAVENOUS AND INTRAMUSCULAR PARECOXIB IN HEALTHY BEAGLES|
|Anno del prodotto:||2012|
|Digital Object Identifier (DOI):||10.1016/j.tvjl.2011.11.005|
|Appare nelle tipologie:||1.1 Articolo in rivista|